Lymphomas are a heterogeneous group of cancer diseases of the lymphatic system.
Lymphomas are divided into Hodgkin’s Lymphomas and Non-Hodgkin’s Lymphomas.
Each of these two groups includes diseases that differ in severity and therapeutic needs.
Essential for a correct treatment of lymphomas is the so-called initial staging of the disease, which through various tests (radiological, histological, blood) defines the extent of each patient’s disease.
Hodgkin’s lymphomas (named after Thomas Hodgkin, English physician 1798-1866, who first described the disease) are characterized by the presence of Reed-Stemberg cell lymph nodes in the tumor tissue. There are several types of Hodgkin’s lymphomas.
The current therapeutic results are remarkable thanks to the progress of chemotherapy and radiotherapy, with high percentages of healings.
Non-Hodgkin’s Lymphomas are a more heterogeneous group of diseases, with very different clinical behaviors, which require very different treatments (from simple clinical observation over time to oral therapies, to more or less aggressive chemotherapies up to hematopoietic marrow transplantation).
Also in this group of diseases, there have been notable developments in the therapeutic field with the introduction of new drugs (monoclonal antibodies, radioimmunotherapy).